Campbell C A, Parratt J R
Br J Pharmacol. 1983 Aug;79(4):939-46. doi: 10.1111/j.1476-5381.1983.tb10539.x.
The effects of several beta-adrenoceptor blocking agents, [+), (-) and (+/-)-oxprenolol, p-oxprenolol, practolol, propranolol and timolol) were investigated on the ventricular arrhythmias occurring within the first 30 min of acutely ligating the main left coronary artery in anaesthetized rats. The degree of cardiac and vascular beta-adrenoceptor blockade was also assessed. All the compounds exhibited antiarrhythmic activity under these conditions. The degree of cardiac beta-adrenoceptor blockade required for this protection was less for the cardioselective agents, p-oxprenolol and practolol, than for the non-selective beta-adrenoceptor blocking agents. A comparison of the two isomers of oxprenolol demonstrated that the (-)-isomer markedly suppressed ischaemic arrhythmias (ventricular ectopic beats, incidence and duration of ventricular tachycardia and duration of ventricular fibrillation) more effectively than the (+)-isomer. Compounds possessing intrinsic sympathomimetic activity (ISA) caused less marked haemodynamic changes (in equivalent beta-blocking doses) than those that did not possess this ancillary property. The membrane stabilizing activity of oxprenolol and p-oxprenolol did not appear to contribute to the antiarrhythmic activity of these agents; however, the membrane stabilizing activity of propranolol may contribute to its effectiveness. In all the drugs studied, the main pharmacological property required to suppress early postischaemic arrhythmias is blockade of cardiac beta-adrenoceptors.
研究了几种β-肾上腺素受体阻滞剂([+)、(-)和(±)-氧烯洛尔、对氧烯洛尔、普拉洛尔、普萘洛尔和噻吗洛尔]对麻醉大鼠急性结扎左冠状动脉主干后30分钟内发生的室性心律失常的影响。还评估了心脏和血管β-肾上腺素受体的阻断程度。在这些条件下,所有化合物均表现出抗心律失常活性。与非选择性β-肾上腺素受体阻滞剂相比,心脏选择性药物对氧烯洛尔和普拉洛尔发挥这种保护作用所需的心脏β-肾上腺素受体阻断程度更低。氧烯洛尔两种异构体的比较表明,(-)-异构体比(+)-异构体更有效地抑制缺血性心律失常(室性早搏、室性心动过速的发生率和持续时间以及室颤的持续时间)。具有内在拟交感活性(ISA)的化合物(在等效的β-阻断剂量下)引起的血流动力学变化比不具有这种辅助特性的化合物小。氧烯洛尔和对氧烯洛尔的膜稳定活性似乎对这些药物的抗心律失常活性没有贡献;然而,普萘洛尔的膜稳定活性可能有助于其有效性。在所有研究的药物中,抑制缺血后早期心律失常所需的主要药理特性是阻断心脏β-肾上腺素受体。